Related Experiment Video
Updated: Jan 25, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
A rare case of sorafenib-induced severe hyponatremia
Misbahuddin Khaja1, Frantz Torchon2, Konstantin Millerman2
1Division of Pulmonary/Critical Care Medicine, Bronx Care Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Background:
Sorafenib is an anti-angiogenic tyrosine kinase inhibitor used to treat patients with renal cell cancer and advanced hepatocellular cancer. Common adverse effects of sorafenib are rash, diarrhea, nausea, and abnormal liver function test and hand-foot syndrome.
Case Presentation:
Here, we present a case of a 90-year-old male who was prescribed sorafenib after being diagnosed with hepatocellular cancer. At 1 week after sorafenib initiation, he was admitted to the emergency room for an evaluation of weakness. The patient had hyponatremia, a common electrolyte abnormality seen in cancer patients. His hyponatremia improved when the sorafenib was stopped, suggesting that this was a rare case of hyponatremia induced by sorafenib.
Conclusion:
Although sorafenib is used in the treatment of hepatocellular cancer, it can cause life-threatening complication such as hyponatremia. Early identification of the cause of hyponatremia can prevent serious adverse event.
Insights
Sorafenib, used for liver cancer, can rarely cause severe low sodium levels (hyponatremia). Stopping the drug improved the patient's condition, highlighting the need for early detection of this adverse effect.
Area of Science:
- Oncology
- Pharmacology
Background:
- Sorafenib is a tyrosine kinase inhibitor for advanced renal cell and hepatocellular carcinoma.
- Common sorafenib side effects include rash, diarrhea, nausea, and hand-foot syndrome.
Observation:
- A 90-year-old male with hepatocellular cancer developed weakness one week after starting sorafenib.
- The patient presented with hyponatremia, a known electrolyte imbalance in cancer patients.
Findings:
- The patient's hyponatremia resolved after discontinuing sorafenib.
- This suggests a rare instance of sorafenib-induced hyponatremia.
Implications:
- Sorafenib, while effective for hepatocellular cancer, carries a risk of serious complications like hyponatremia.
- Prompt identification and management of sorafenib-induced hyponatremia are crucial to prevent adverse outcomes.
Related Concept Videos
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
Spontaneous and Induced Mutations
Induced Electric Dipoles
Since the absolute value of potential energy holds no physical meaning, its zero value can be chosen as per...
Induced Electric Fields

